MX384605B - Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno. - Google Patents

Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.

Info

Publication number
MX384605B
MX384605B MX2017013802A MX2017013802A MX384605B MX 384605 B MX384605 B MX 384605B MX 2017013802 A MX2017013802 A MX 2017013802A MX 2017013802 A MX2017013802 A MX 2017013802A MX 384605 B MX384605 B MX 384605B
Authority
MX
Mexico
Prior art keywords
subject
rad1901
palbociclib
combination
treatment
Prior art date
Application number
MX2017013802A
Other languages
English (en)
Spanish (es)
Other versions
MX2017013802A (es
Inventor
Gary Hattersley
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57198783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX384605(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of MX2017013802A publication Critical patent/MX2017013802A/es
Publication of MX384605B publication Critical patent/MX384605B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2017013802A 2015-04-29 2016-04-29 Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno. MX384605B (es)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201562154699P 2015-04-29 2015-04-29
US201562155451P 2015-04-30 2015-04-30
US201562158469P 2015-05-07 2015-05-07
US201562192940P 2015-07-15 2015-07-15
US201562192944P 2015-07-15 2015-07-15
US201562252085P 2015-11-06 2015-11-06
US201562252916P 2015-11-09 2015-11-09
US201562265658P 2015-12-10 2015-12-10
US201562265696P 2015-12-10 2015-12-10
US201562265774P 2015-12-10 2015-12-10
US201562265663P 2015-12-10 2015-12-10
US201662323572P 2016-04-15 2016-04-15
US201662323576P 2016-04-15 2016-04-15
PCT/US2016/030321 WO2016176666A1 (en) 2015-04-29 2016-04-29 Methods of treating cancer

Publications (2)

Publication Number Publication Date
MX2017013802A MX2017013802A (es) 2018-08-15
MX384605B true MX384605B (es) 2025-03-14

Family

ID=57198783

Family Applications (6)

Application Number Title Priority Date Filing Date
MX2017013802A MX384605B (es) 2015-04-29 2016-04-29 Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
MX2017013794A MX394676B (es) 2015-04-29 2016-04-29 Métodos para tratar el cáncer.
MX2021005561A MX393599B (es) 2015-04-29 2016-04-29 Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
MX2017013801A MX384908B (es) 2015-04-29 2016-04-29 Rad1901 para usarse en el tratamiento de cáncer en sujetos con cáncer positivo a receptor de estrógeno alfa resistente a farmaco.
MX2021004881A MX2021004881A (es) 2015-04-29 2017-10-26 Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno.
MX2021003389A MX2021003389A (es) 2015-04-29 2017-10-26 Metodos para tratar el cancer.

Family Applications After (5)

Application Number Title Priority Date Filing Date
MX2017013794A MX394676B (es) 2015-04-29 2016-04-29 Métodos para tratar el cáncer.
MX2021005561A MX393599B (es) 2015-04-29 2016-04-29 Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
MX2017013801A MX384908B (es) 2015-04-29 2016-04-29 Rad1901 para usarse en el tratamiento de cáncer en sujetos con cáncer positivo a receptor de estrógeno alfa resistente a farmaco.
MX2021004881A MX2021004881A (es) 2015-04-29 2017-10-26 Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno.
MX2021003389A MX2021003389A (es) 2015-04-29 2017-10-26 Metodos para tratar el cancer.

Country Status (14)

Country Link
US (12) US20180153828A1 (enExample)
EP (4) EP3288382A4 (enExample)
JP (9) JP6926065B2 (enExample)
KR (9) KR20250152678A (enExample)
CN (5) CN113750091B (enExample)
AU (3) AU2016256469B2 (enExample)
BR (3) BR112017023228A2 (enExample)
CA (2) CA2984200C (enExample)
HK (3) HK1251409A1 (enExample)
IL (10) IL297369B2 (enExample)
MX (6) MX384605B (enExample)
RU (3) RU2747228C2 (enExample)
SG (4) SG11201708858WA (enExample)
WO (3) WO2016176666A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
MX384605B (es) 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
SG11201806829TA (en) 2016-02-15 2018-09-27 Sanofi Sa 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
AU2017336564A1 (en) * 2016-09-27 2019-03-14 Radius Pharmaceuticals, Inc. Methods for treating ovarian cancer
CN110099680B (zh) 2016-10-11 2021-02-05 杜克大学 Er+乳腺癌的拉索昔芬治疗
EP3541809B1 (en) 2016-11-17 2025-06-25 Sanofi Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
WO2018170447A1 (en) * 2017-03-16 2018-09-20 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
US12012421B2 (en) 2017-07-07 2024-06-18 Hoffmann-La Roche Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
US11179365B2 (en) 2017-11-16 2021-11-23 Novartis Ag Pharmaceutical combination comprising LSZ102 and ribociclib
US12012420B2 (en) 2017-11-21 2024-06-18 Hoffmann-La Roche, Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
WO2019106604A1 (en) 2017-12-01 2019-06-06 Novartis Ag Pharmaceutical combination comprising lsz102 and alpelisib
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
CN110585429B (zh) * 2018-06-12 2022-10-21 江苏恒瑞医药股份有限公司 酪氨酸激酶抑制剂联合单克隆抗体以及紫杉醇类药物治疗肿瘤疾病的用途
SG11202013177WA (en) * 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
DK3847157T3 (da) 2018-09-07 2022-08-08 Sanofi Sa Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
WO2020112765A1 (en) * 2018-11-30 2020-06-04 Radius Pharmaceuticals, Inc. Elacestrant in combination with abemaciclib in women with breast cancer
MX2021006411A (es) * 2018-12-06 2021-07-21 Radius Pharmaceuticals Inc Metodos para el tratamiento del cancer resistente a inhibidores de cinasa 4 y cinasa 6 dependiente de ciclina (cdk4/6).
CA3121918A1 (en) * 2018-12-06 2020-06-11 Radius Pharmaceuticals, Inc. Methods for treating cancer in models harboring esr1 mutations
SG11202105889YA (en) * 2018-12-12 2021-07-29 Chemocentryx Inc Cxcr7 inhibitors for the treatment of cancer
US12441745B2 (en) 2019-02-12 2025-10-14 Radius Pharmaceuticals, Inc. Processes and compounds
SG11202111979SA (en) * 2019-05-09 2021-11-29 Sanofi Sa 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients
CA3144791A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
KR102341347B1 (ko) * 2019-11-28 2021-12-20 의료법인 성광의료재단 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법
CA3160897A1 (en) 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
MX2022010425A (es) * 2020-03-06 2022-09-07 Olema Pharmaceuticals Inc Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
US20210330653A1 (en) * 2020-04-24 2021-10-28 Astrazeneca Ab Dosage Regimen for the Treatment of Cancer
KR20230009390A (ko) * 2020-05-12 2023-01-17 제넨테크, 인크. Gdc-9545 및 cdk4/6 억제제를 포함하는 병용 요법을 사용한 유방암 치료
BR112023002161A2 (pt) * 2020-08-05 2023-04-04 Aizant Drug Res Solutions Private Limited Formas sólidas de dosagem de palbociclibe
IL302152B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
IL302153B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
IL303143A (en) * 2020-12-14 2023-07-01 Arvinas Operations Inc Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
JP7846700B2 (ja) * 2021-02-16 2026-04-15 ジェネンテック， インコーポレイテッド Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療
CN113662942B (zh) * 2021-08-19 2023-02-07 中国人民解放军陆军军医大学第一附属医院 药物组合物及其在smo突变性髓母细胞瘤中的应用
WO2023064519A1 (en) 2021-10-14 2023-04-20 Teva Pharmaceuticals International Gmbh Solid state forms of elacestrant and processes for preparation thereof
DE102021130035A1 (de) 2021-11-17 2023-05-17 USound GmbH MEMS-Schallwandler mit einer gekrümmten Kontur eines Kragarmelements
US12555854B2 (en) 2021-11-18 2026-02-17 Globus Medical Inc. Vacuum insulated battery
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
WO2024104268A1 (zh) * 2022-11-15 2024-05-23 苏州科睿思制药有限公司 艾拉司群二盐酸盐的共晶及其制备方法和用途
KR20240105964A (ko) * 2022-12-29 2024-07-08 주식회사 삼양홀딩스 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법
EP4574811A1 (en) 2023-12-22 2025-06-25 Sandoz Ag Crystalline forms of elacestrant dihydrochloride
WO2025158416A1 (en) 2024-01-25 2025-07-31 Assia Chemical Industries Ltd. Solid state forms of elacestrant and processes for preparation thereof

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939346A1 (de) 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
DE19517430A1 (de) 1995-05-12 1996-11-14 Boehringer Mannheim Gmbh Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
IT1285405B1 (it) 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
DE19538687A1 (de) 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
TW505654B (en) 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
ATE497001T1 (de) 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
BR9812068A (pt) 1997-09-09 2000-09-26 Hoffmann La Roche Processo para a cicatrização óssea e restauração de fraturas e utilização de um análogo de polipeptìdeo de peptìdeo (pthrp) relacionado com hormÈnios de paratireóide e seus sais
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
PT1037686E (pt) 1997-12-11 2005-10-31 Alza Corp Aparelho para potenciar o fluxo de agente transdermico
CN1161164C (zh) 1997-12-11 2004-08-11 阿尔扎有限公司 用于通过体表导入或提取质剂的装置
EP0922467A3 (en) 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
JP4154017B2 (ja) 1997-12-30 2008-09-24 久光製薬株式会社 イオントフォレーシス装置および薬物ユニット
US6091975A (en) 1998-04-01 2000-07-18 Alza Corporation Minimally invasive detecting device
SE9801495D0 (sv) 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6316410B1 (en) 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
AU1280701A (en) 1999-11-17 2001-05-30 Novartis Ag Iontophoretic transdermal delivery of peptides
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US20010044431A1 (en) 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
CA2418135C (en) 2000-08-03 2011-09-20 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
WO2002016316A1 (en) 2000-08-23 2002-02-28 Akzo Nobel N.V. 10-ARYL-11-HBENZO [b]FLUORENE DERIVATIVES AND ANALOGS FOR MEDICINAL USE
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
CA2427381A1 (en) 2000-10-26 2002-11-28 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
NZ529029A (en) 2001-04-20 2005-07-29 Alza Corp Microprojection array having a beneficial agent containing coating
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
US6881203B2 (en) 2001-09-05 2005-04-19 3M Innovative Properties Company Microneedle arrays and methods of manufacturing the same
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
GB0129457D0 (en) 2001-12-10 2002-01-30 Astrazeneca Ab Method of treatment
US20030181936A1 (en) 2001-12-20 2003-09-25 Trautman Joseph C. Skin-piercing microprojections having piercing depth control
WO2003063859A1 (en) 2002-01-14 2003-08-07 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
US20050009739A1 (en) 2002-02-14 2005-01-13 Wei Wang Formulation strategies in stabilizing peptides in organic solvents and in dried states
AU2003239869A1 (en) 2002-05-23 2003-12-12 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
TW200307553A (en) 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
US7799757B2 (en) 2002-06-13 2010-09-21 Michael Chorev Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents
WO2004007520A2 (en) 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
WO2004009172A1 (en) 2002-07-19 2004-01-29 3M Innovative Properties Company Microneedle devices and microneedle delivery apparatus
KR20050059258A (ko) 2002-10-14 2005-06-17 노보 노르디스크 에이/에스 Ｇｌｐ-2 화합물, 제제, 및 그것의 사용
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
US8133505B2 (en) 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US7383084B2 (en) 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
IL152574A (en) 2002-10-31 2009-09-22 Transpharma Medical Ltd A system for passing through the skin of dry items or dried medicines
US7662404B2 (en) 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
AU2002359391A1 (en) 2002-11-01 2004-07-29 Amgen, Inc. Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein
CA2512000C (en) * 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
WO2004110978A2 (en) 2003-06-10 2004-12-23 Smithkline Beecham Corporation 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors
WO2005000795A2 (en) 2003-06-10 2005-01-06 Smithkline Beecham Corporation Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
CA2530531A1 (en) 2003-06-30 2005-01-20 Alza Corporation Formulations for coated microprojections containing non-volatile counterions
BRPI0412021A (pt) 2003-06-30 2006-08-15 Alza Corp método para revestir microprojeções de perfuração de pele
WO2005014034A1 (en) 2003-07-14 2005-02-17 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
US7141544B2 (en) 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
JP2007535337A (ja) 2003-10-28 2007-12-06 アルザ・コーポレーシヨン 被覆された微小突起による治療用ペプチドおよびタンパクのポリマー接合体の送達
US7097631B2 (en) 2003-10-31 2006-08-29 Alza Corporation Self-actuating applicator for microprojection array
CA2546280A1 (en) 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
CA2545048A1 (en) 2003-11-20 2005-06-02 Warner-Lambert Company Llc Androgen receptor modulators
MXPA06005677A (es) 2003-11-21 2006-12-14 Johnson & Johnson Metodo y sistema de suministro transdermico de vacuna asistido por ultrasonido.
IL159273A0 (en) 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
CN1930181A (zh) 2004-01-07 2007-03-14 恩多研究公司 螺旋12定向的甾族药品
IL160033A0 (en) 2004-01-25 2004-06-20 Transpharma Medical Ltd Transdermal delivery system for polynucleotides
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
GB0405033D0 (en) 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
CA2562132A1 (en) 2004-04-08 2005-10-27 Merck & Co., Inc. 17 beta-acetamide-4-azasteroids as androgen receptor modulators
US7244709B2 (en) 2004-05-10 2007-07-17 Nastech Pharamecutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
MXPA06013115A (es) 2004-05-11 2007-02-28 Pfizer Prod Inc Derivados de benzonitrilo para tratar la fragilidad musculoesqueletica.
MXPA06013168A (es) 2004-05-13 2007-05-15 Johnson & Johnson Aparato y metodo para el suministro transdermico de agentes de la hormona paratiroidea.
US7906137B2 (en) 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
WO2005113008A1 (en) 2004-05-21 2005-12-01 Mediplex Corp. Delivery agents for enhancing mucosal absorption of therapeutic agents
US20090069226A1 (en) 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
AU2005310238A1 (en) 2004-10-29 2006-06-08 Merck Sharp & Dohme Corp. N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
US8057842B2 (en) 2004-11-18 2011-11-15 3M Innovative Properties Company Method of contact coating a microneedle array
WO2006055799A1 (en) 2004-11-18 2006-05-26 3M Innovative Properties Company Masking method for coating a microneedle array
EP1848498A4 (en) 2004-11-18 2009-12-16 Transpharma Medical Ltd ASSOCIATED MICRO-CHANNEL PRODUCTION AND IONTOPHORESIS FOR TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS
AU2006206272A1 (en) 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
JP2008536868A (ja) 2005-04-15 2008-09-11 スミスクライン・ビーチャム・コーポレイション シアノアリールアミン
KR100700869B1 (ko) 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
JP2008546643A (ja) 2005-06-06 2008-12-25 スミスクライン ビーチャム コーポレーション ４−置換アリールアミン誘導体および医薬組成物におけるその使用
US20090227571A1 (en) 2005-07-01 2009-09-10 Ligand Pharmaceuticals Incorporated Androgen Receptor Modulator Compounds and Methods
US20070021216A1 (en) 2005-07-19 2007-01-25 Sony Ericsson Mobile Communications Ab Seamless gaming method and apparatus
JP2008303145A (ja) 2005-09-22 2008-12-18 Takeda Chem Ind Ltd Ｇｒｋ阻害剤からなる強心薬
WO2007061781A1 (en) 2005-11-18 2007-05-31 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
JP2009522288A (ja) 2005-12-28 2009-06-11 アルザ コーポレイション 安定な治療剤形
WO2007106597A2 (en) 2006-03-15 2007-09-20 Alza Corporation Method for the transdermal delivery of parathyroid hormone agents for treating osteopenia
WO2007124465A2 (en) 2006-04-20 2007-11-01 Amgen Inc. Stable emulsion formulations
US9119945B2 (en) 2006-04-20 2015-09-01 3M Innovative Properties Company Device for applying a microneedle array
CA2649388A1 (en) 2006-04-20 2007-11-01 Velocys, Inc. Process for treating and/or forming a non-newtonian fluid using microchannel process technology
CN101085743B (zh) 2006-06-06 2012-02-15 浙江大德药业集团有限公司 含氟烷氧基康普立停衍生物及制法和用途
CA2656067C (en) 2006-06-23 2014-08-12 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
ES2780193T3 (es) 2006-07-12 2020-08-24 Univ Tennessee Res Found Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina
AU2007287070C1 (en) 2006-08-24 2013-02-14 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US8207115B2 (en) 2006-08-25 2012-06-26 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
CN1927815A (zh) 2006-09-25 2007-03-14 天津理工大学 邻苄胺基苯基醚化合物、化合物的衍生物及其制备方法与用途
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
DK2073789T3 (da) 2006-10-03 2019-08-05 Radius Health Inc Stabil sammensætning omfattende et knogle-anabolisk protein, nemlig en pthrp-analog, og anvendelser deraf
WO2008044033A1 (en) 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
ES2473620T3 (es) 2007-02-06 2014-07-07 Hisamitsu Pharmaceutical Co., Inc. Dispositivo de microagujas para el diagnóstico de una alergia
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
WO2008130587A2 (en) 2007-04-16 2008-10-30 Corium International, Inc. Solvent-cast microneedle arrays containing active
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
CA2688049A1 (en) 2007-05-31 2008-12-04 Dako Denmark A/S Methods for utilizing esr copy number changes in breast cancer treatments and prognoses
MX2009013575A (es) 2007-06-12 2010-07-02 Schering Corp Biomarcador de histona h2ax (hh2ax) para sensibilidad de inhibidores de farnesil proteina transferasa.
US8450481B2 (en) 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
US20120150023A1 (en) 2007-08-06 2012-06-14 Kaspar Roger L Microneedle arrays for active agent delivery
EP2205169B1 (en) 2007-09-28 2016-11-16 The Queen's University of Belfast Delivery device and method
US20090117158A1 (en) 2007-10-23 2009-05-07 Mahmoud Ameri Transdermal sustained release drug delivery
EP2052736A1 (en) 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
CN101795680A (zh) 2007-11-16 2010-08-04 波苏蛋白试剂公司 稳定蛋白质的辅剂
WO2009133861A1 (ja) 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
US20110124617A1 (en) * 2008-05-09 2011-05-26 Lyttle C Richard Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent
WO2010022176A1 (en) 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
CN104013569A (zh) 2008-10-15 2014-09-03 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
RU2561057C2 (ru) 2008-11-04 2015-08-20 Аска Фармасьютикал Ко., Лтд. Водная композиция, содержащая фолликулостимулирующий гормон
KR20160150109A (ko) 2008-11-18 2016-12-28 쓰리엠 이노베이티브 프로퍼티즈 컴파니 중공 마이크로니들 어레이
KR101634836B1 (ko) 2008-12-26 2016-06-29 히사미쓰 세이야꾸 가부시키가이샤 마이크로 니들 디바이스
US20100203014A1 (en) 2009-02-04 2010-08-12 Aegis Therapeutics Llc Zwitterionic buffered acidic peptide and protein formulations
US20100226966A1 (en) 2009-03-03 2010-09-09 Daddona Peter E Method for transdermal controlled release drug delivery
WO2010118287A1 (en) 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
JP5820805B2 (ja) 2009-04-24 2015-11-24 コリウム インターナショナル， インコーポレイテッド マイクロプロジェクションのアレイの製造のためのプロセス
AU2010276511B2 (en) 2009-07-31 2013-09-19 Kindeva Drug Delivery L.P. Hollow microneedle arrays
US20120219538A1 (en) 2009-11-02 2012-08-30 Therapeomic Ag Stabilized protein formulations and use thereof
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
CN101912600B (zh) 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
IE20100174A1 (en) 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
JP6327852B2 (ja) 2010-05-04 2018-05-23 コリウム インターナショナル， インコーポレイテッド 微小突起アレイを使用した副甲状腺ホルモンの経皮送達のための方法及びデバイス
AU2011258288B2 (en) 2010-05-28 2015-02-12 Kindeva Drug Delivery L.P. Aqueous formulations for coating microneedle arrays
SG186333A1 (en) * 2010-06-16 2013-01-30 Endorech Inc Methods of treating or preventing estrogen-related diseases
WO2012075375A1 (en) 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
EP2680871A4 (en) 2011-03-01 2015-04-22 Sloan Kettering Inst Cancer SYMBOLS HORMONE ANALOGUE, COMPOSITIONS THEREOF AND USES THEREOF
KR20140047043A (ko) 2011-04-22 2014-04-21 라디우스 헬쓰, 인코포레이티드 PTH, PTHrP를 위한 약물 전달 방법 및 관련 펩티드
AU2012345777B2 (en) 2011-11-30 2016-05-12 Kindeva Drug Delivery L.P. Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
GB201217439D0 (en) 2012-09-28 2012-11-14 Topotarget As Combination therapy
WO2014203129A1 (en) * 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
CN104436194B (zh) 2013-09-18 2018-03-30 北京大学 具有协同增效作用的抗癌组合物
WO2015113062A1 (en) * 2014-01-27 2015-07-30 Dna-Seq, Inc. Methods and systems for determination of an effective therapeutic regimen and drug discovery
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
ES2939940T3 (es) * 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
AR104068A1 (es) * 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
MX384605B (es) 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.

Also Published As

Publication number Publication date
KR102871388B1 (ko) 2025-10-14
AU2016256470B2 (en) 2020-10-15
MX2017013802A (es) 2018-08-15
US11819480B2 (en) 2023-11-21
CN113750091A (zh) 2021-12-07
CN108024540A (zh) 2018-05-11
MX2017013794A (es) 2018-08-15
MX384908B (es) 2025-03-14
WO2016176666A1 (en) 2016-11-03
MX2017013801A (es) 2018-08-15
RU2017140676A (ru) 2019-05-29
IL307981A (en) 2023-12-01
IL297369B2 (en) 2024-06-01
JP7019422B2 (ja) 2022-02-15
MX394676B (es) 2025-03-24
NZ737825A (en) 2024-10-25
IL319266A (en) 2025-04-01
BR112017023233A2 (en) 2018-11-06
KR102676705B1 (ko) 2024-06-18
JP2021105064A (ja) 2021-07-26
EP3294065A1 (en) 2018-03-21
MX2021003389A (es) 2021-05-28
IL255148B2 (en) 2023-04-01
CA2984200C (en) 2024-03-19
IL255261B2 (en) 2024-03-01
US20250367141A1 (en) 2025-12-04
JP2018514549A (ja) 2018-06-07
US20240099996A1 (en) 2024-03-28
SG11201708860SA (en) 2017-11-29
RU2017140676A3 (enExample) 2019-09-27
US20250367140A1 (en) 2025-12-04
IL307983B1 (en) 2025-11-01
HK1251407A1 (zh) 2019-02-01
JP7696378B2 (ja) 2025-06-20
AU2016256469A1 (en) 2017-12-14
IL255189A0 (en) 2017-12-31
JP2022172039A (ja) 2022-11-14
RU2745678C2 (ru) 2021-03-30
IL255189B1 (en) 2023-12-01
KR20250152678A (ko) 2025-10-23
IL307983B2 (en) 2026-03-01
WO2016176664A1 (en) 2016-11-03
RU2017140674A3 (enExample) 2019-09-27
US12582617B2 (en) 2026-03-24
CA2984200A1 (en) 2016-11-03
CA2984357A1 (en) 2016-11-03
KR102871380B1 (ko) 2025-10-14
JP6926066B2 (ja) 2021-08-25
IL255148A0 (en) 2017-12-31
JP6926065B2 (ja) 2021-08-25
JP2021102640A (ja) 2021-07-15
MX393599B (es) 2025-03-19
HK1251408A1 (zh) 2019-02-01
IL297369B1 (en) 2024-02-01
RU2017140675A3 (enExample) 2019-09-27
IL307981B2 (en) 2026-03-01
IL323924A (en) 2025-12-01
SG10202104177VA (en) 2021-05-28
IL255148B (en) 2022-12-01
IL297369A (en) 2022-12-01
SG11201708861VA (en) 2017-11-29
IL255261A0 (en) 2017-12-31
JP2025170141A (ja) 2025-11-14
JP7745708B2 (ja) 2025-09-29
KR102682763B1 (ko) 2024-07-05
IL307981B1 (en) 2025-11-01
MX2021004881A (es) 2021-07-21
KR20240097966A (ko) 2024-06-27
JP7262508B2 (ja) 2023-04-21
US20220339126A1 (en) 2022-10-27
NZ737822A (en) 2024-10-25
US20180169101A1 (en) 2018-06-21
KR20240110098A (ko) 2024-07-12
KR102871408B1 (ko) 2025-10-14
MX2021005561A (es) 2022-07-01
CN108024541B (zh) 2021-07-20
US20180214393A1 (en) 2018-08-02
AU2016256471B2 (en) 2020-09-10
JP2023052631A (ja) 2023-04-11
JP2018518529A (ja) 2018-07-12
RU2017140674A (ru) 2019-05-29
CA2984195C (en) 2023-10-24
CN108135177A (zh) 2018-06-08
IL310069A (en) 2024-03-01
SG11201708858WA (en) 2017-11-29
JP7516472B2 (ja) 2024-07-16
IL307983A (en) 2023-12-01
US20200046655A1 (en) 2020-02-13
RU2747228C2 (ru) 2021-04-29
KR20250153309A (ko) 2025-10-24
IL323926A (en) 2025-12-01
KR20250152679A (ko) 2025-10-23
EP3288383A4 (en) 2019-01-23
EP3288383A1 (en) 2018-03-07
CN108135177B (zh) 2021-06-01
CN108024541A (zh) 2018-05-11
RU2017140675A (ru) 2019-05-29
BR112017023228A2 (en) 2018-11-06
NZ737819A (en) 2024-10-25
RU2737496C2 (ru) 2020-12-01
US20240091177A1 (en) 2024-03-21
EP3288382A4 (en) 2019-01-30
US20220110890A1 (en) 2022-04-14
IL255189B2 (en) 2024-04-01
JP7146992B2 (ja) 2022-10-04
US11413258B2 (en) 2022-08-16
KR20180042155A (ko) 2018-04-25
JP2024120996A (ja) 2024-09-05
AU2016256469A8 (en) 2017-12-21
WO2016176665A1 (en) 2016-11-03
CN113750091B (zh) 2025-03-11
AU2016256471A1 (en) 2017-12-21
JP2018514593A (ja) 2018-06-07
AU2016256470A1 (en) 2017-12-14
KR20240095372A (ko) 2024-06-25
KR102676629B1 (ko) 2024-06-18
EP3294065A4 (en) 2019-03-20
KR20180043202A (ko) 2018-04-27
CN113288887A (zh) 2021-08-24
IL310069B2 (en) 2025-08-01
IL255261B1 (en) 2023-11-01
US12263141B2 (en) 2025-04-01
IL310069B1 (en) 2025-04-01
US20200038343A1 (en) 2020-02-06
BR112017023269A2 (en) 2018-11-06
EP3288382A1 (en) 2018-03-07
EP4039253A1 (en) 2022-08-10
CA2984195A1 (en) 2016-11-03
HK1251409A1 (zh) 2019-02-01
US20200368183A1 (en) 2020-11-26
KR20180011780A (ko) 2018-02-02
AU2016256469B2 (en) 2020-12-10
CN108024540B (zh) 2021-09-17
US20180153828A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
MX2021004881A (es) Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno.
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
JO3589B1 (ar) مثبطات كيناز البروتين c وطرق استخداماتها
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
MX2017000168A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2017002824A (es) Inhibidores demetilasa-1 especifica de lisina.
CL2016003350A1 (es) Inhibidores de demetilasa-1 especifica de lisina
MX2016007585A (es) Inhibidores de desmetilasa-1 especifica de lisina.
MX2016014007A (es) Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab.
CO2017000359A2 (es) Compuestos derivados de piridina sustituidos como inhibidores de histonas desmetilasa
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
MX2023011187A (es) Metodos para tratar el cancer de prostata.
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
IN2014MU00303A (enExample)
IL270716A (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
IL269357A (en) Combination therapies for the treatment of breast cancer
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
IL284981A (en) Semaphorin-4d antagonists for use in cancer therapy
IL252639A0 (en) Breast cancer treatment using taxane
BR112019025164A2 (pt) Esquema de dosagem para tesetaxel e capecitabina
EA201990411A1 (ru) Способы лечения рака предстательной железы
NZ790573A (en) Methods of treating prostate cancer
GB201718806D0 (en) Breast cancer treatment
PH12014000105A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds